Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)

CAPS Rating: 1 out of 5

The Company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs.

Results 1 - 13 of 13

Recs

0
Member Avatar pchop12316 (79.62) Submitted: 8/20/2014 4:11:33 PM : Underperform Start Price: $7.26 SNSS Score: +4.28

volatile & overpriced

Recs

0
Member Avatar pchop123 (79.66) Submitted: 7/31/2014 12:41:04 PM : Underperform Start Price: $6.63 SNSS Score: -2.25

overpriced

Recs

2
Member Avatar zzlangerhans (99.77) Submitted: 7/31/2014 10:29:30 AM : Underperform Start Price: $7.15 SNSS Score: +4.09

Sunesis is still oddly volatile and out of sync with the small cap biotech segment ahead of VALOR unblinding, now pushed back to the end of Q3 or early Q4. This data has been delayed so many times I've lost count, and for reasons I've delineated countless times on these pages I expect it to be negative. As always, when the share price moves up out of the recent trading range without any identifiable catalyst I'm there with a red thumb until it goes back down. The only real question is if data will end up getting pushed back to 2015. This time I'm short 1000 shares in real life at 6.97.

Recs

0
Member Avatar motleyflyer (< 20) Submitted: 1/30/2013 7:21:31 AM : Outperform Start Price: $4.97 SNSS Score: +17.64

Pharma Research

Recs

0
Member Avatar SnarkyApple (48.38) Submitted: 9/27/2012 4:32:36 PM : Underperform Start Price: $5.67 SNSS Score: +15.68

Shenanigans.

Recs

0
Member Avatar theMANzalone (69.38) Submitted: 3/14/2012 4:05:12 PM : Outperform Start Price: $2.45 SNSS Score: +142.64

2013 will kick into gear

Recs

0
Member Avatar DanishDynamite (< 20) Submitted: 7/22/2011 4:38:21 AM : Outperform Start Price: $2.04 SNSS Score: +194.10

Finally, found its price range, before we reach a yes or no, it will spike on phase III news.

Recs

0
Member Avatar stemcells2011 (86.32) Submitted: 3/1/2011 10:56:34 AM : Outperform Start Price: $2.07 SNSS Score: +187.20

Very bullish long term.

Recs

0
Member Avatar archingstocks (< 20) Submitted: 1/10/2011 5:23:50 PM : Outperform Start Price: $2.97 SNSS Score: +78.25

Well funded, well staffed, good drug

Recs

2
Member Avatar akshara3000 (< 20) Submitted: 1/5/2011 6:10:19 PM : Outperform Start Price: $3.00 SNSS Score: +76.96

If phase 3 trial info is released midterm through the study, and it is as positive and consistent as previous results, the stock will jump remarkably, especially after being beaten down so badly since mid 2010. This thing could easily double or triple in a years time, since there is no reason not to believe that phase 3 results will be outstanding. That does not guarantee approval, but there should be money to be made well before that stage of the process. 25k shares at 66 cents and I will hold long term

Recs

0
Member Avatar 1997amer (< 20) Submitted: 1/1/2011 5:05:18 PM : Outperform Start Price: $3.12 SNSS Score: +66.14

It is an oncology orphan drug!!! very likely wii be approved even with 4 -5 weeks improved survival.

Recs

0
Member Avatar motleyjmw (< 20) Submitted: 1/19/2007 1:48:31 PM : Outperform Start Price: $30.00 SNSS Score: -125.67

Biogen Idec is a beneficial owner

Recs

0
Member Avatar theminc (< 20) Submitted: 10/6/2006 9:28:50 PM : Underperform Start Price: $30.00 SNSS Score: +134.46

Early in the IPO. Solid company with a lot of bright minds. Results of clinical trial results will determine level of success.

Results 1 - 13 of 13

Featured Broker Partners


Advertisement